“…Mass-spectrometry-based proteomics amyloid typing in clinical practice: state-of-the-art from a French nationwide cohort Short title: amyloid typing using mass spectrometry Magali Colombat 1 , Margot Gaspard 1 , Mylène Camus 2,3 , Jessica Dalloux-Chioccioli 1 , Audrey Delas 1 , Elsa Poullot 4 , Anissa Moktefi 4,5 , Arnaud François 6 , Anne Moreau 7 , Jean-Bapiste Gibier 8 , Pierre Raynaud 9 , Antoine Huart 10 , Alexis Piedrafita 10,11 , Julia Gilhodes 12 , Olivier Lairez 13 , Gilles Grateau 14 , Sophie Georgin-Lavialle 14 , Hervé Maisonneuve 15 , Philippe Moreau 16 , Arnaud Jaccard 17 , Franck Bridoux 18 , Violaine Plante-Bordeneuve 5,19 Amyloidosis refers to a large spectrum of diseases, all characterized by the deposition of extracellular misfolded proteins in the form of insoluble highly ordered amyloid fibrils in one (localized amyloidosis) or multiple tissues (systemic amyloidosis). [1][2][3] Amyloid deposits progressively disrupt tissue structure and exert toxic effect on the adjacent cells that ultimately result in organ dysfunction.…”